Evidence map›Paper›PMID 36708412›Full record

SynthesisEuropean journal of epidemiology2023

Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis.

Mojgan Amiri, Hamidreza Raeisi-Dehkordi, Auke J C F Verkaar, Yahong Wu, Anniek C van Westing, Kirsten A Berk, Wichor M Bramer, Dagfinn Aune, Trudy Voortman

Open access · hybridAbstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.Cardiovascular & hematological disorders drug targets · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Mojgan Amiri *Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-4936-4609
Hamidreza Raeisi-Dehkordi *Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Auke J C F VerkaarDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Yahong WuDepartment of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Anniek C van WestingDepartment of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Kirsten A BerkDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Wichor M BramerMedical Library, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Dagfinn AuneDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Trudy VoortmanDepartment of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. trudy.voortman@erasmusmc.nl.ORCID http://orcid.org/0000-0003-2830-6813
Erasmus MC · NLOslo University Hospital · NOUniversity of Bern · CHWageningen University & Research · NL

Funding

Covidence Global Scholarship Program 2022 Covidence Global Scholarship Program 2022
6 · The paper itself

Abstract

aimsTo investigate the association between circulating lipoprotein(a) (Lp(a)) and risk of all-cause and cause-specific mortality in the general population and in patients with chronic diseases, and to elucidate the dose-response relations. METHODS AND

resultsWe searched literature to find prospective studies reporting adjusted risk estimates on the association of Lp(a) and mortality outcomes. Forty-three publications, reporting on 75 studies (957,253 participants), were included. The hazard ratios (HRs) and 95% confidence intervals (95%CI ) for the top versus bottom tertile of Lp(a) levels and risk of all-cause mortality were 1.09 (95%CI: 1.01-1.18, I

conclusionThis study provides further evidence that higher Lp(a) levels are associated with higher risk of all-cause mortality and CVD-death in the general population and in patients with CVD. These findings support the ESC/EAS Guidelines that recommend Lp(a) should be measured at least once in each adult person's lifetime, since our study suggests those with higher Lp(a) might also have higher risk of mortality.

Indexed as

Cardiovascular DiseasesLipoprotein(a)AdultCause of DeathHumansProspective StudiesRisk FactorsLipoprotein(a)Cardiovascular diseaseCause of deathChronic diseaseCohort studiesHeart disease risk factorsLipoprotein(a)Meta-analysisMortalitySurvival

Identifiers

PMID36708412
PMCPMC10164031
OpenAlexW4318338226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.